Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIFE2: Low molecular weight heparin in women with recurrent miscarriage and inherited thrombophilia
2012-001447-43Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of enoxaparin in recurrent miscarriage (RPL), Congenital Thrombophilia and miscarriage (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Live birth. Started Sep 2018; status: completed.
02
Drugs
enoxaparin
03
Conditions
recurrent miscarriage (RPL)Congenital Thrombophiliamiscarriage
Beyond the preview
Go deeper on 2012-001447-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001447-43.